Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
125mg adalimumab-680LT and 15/25 mg risankizumab-800CW[2] Adalimumab,
Risankizumab (Risankizumab)		[2] Adalimumab ,
Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 		[2] IL23A,
TNF 💬 		[69] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[2] 96, 97 💬
2Anti-IL12/23 or anti-IL23 - Risankizumab[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
3Risankizumab[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[4] 37, 96, 97, 271 💬
4Risankizumab (RISA)[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
5Risankizumab 10 mg/ml[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
6Risankizumab 180 mg SC[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
7Risankizumab 600 mg IV[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
8Risankizumab 90 mg/ml[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
9Risankizumab IV[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
10Risankizumab On-Body Injector (OBI)[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
11Risankizumab SC[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
12Risankizumab-800CW 15 mg[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
13Risankizumab-800CW 15 mg/25 mg[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
14Risankizumab-800CW 25 mg[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
15Risankizumab-800CW 4.5 mg[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
16Risankizumab-800CW optimal dose[1] Risankizumab (Risankizumab)[1] Risankizumab (Risankizumab, Risankizumab-rzaa) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
17RisankizumabProduct Code: ABBV-006Pharmaceutical Form: Solution for infusionINN or Proposed INN: RISANKIZUMABCurrent Sponsor code: ABBV-066Concentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 90-Pharmaceutical form of the placebo: Solution for infusionRoute of administration of the placebo: Intravenous useProduct Name: RisankizumabProduct Code: ABBV-066Pharmaceutical Form: Solution for injection in pre-filled syringeINN or Proposed INN: RISANKIZUMABCurrent Sponsor code: ABBV-066Concentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 90-Pharmaceutical form of the placebo: Solution for injection in pre-filled syringeRoute of administration of the placebo: Subcutaneous useProduct Name: RisankizumabProduct Code: ABBV-006Pharmaceutical Form: Solution for infusionINN or Proposed INN: RISANKIZUMABCurrent Sponsor code: ABBV-066Concentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 60-----[1] 97 💬